ProfileGDS5678 / 1447794_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 61% 59% 60% 64% 64% 61% 60% 60% 61% 60% 62% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8207163
GSM967853U87-EV human glioblastoma xenograft - Control 23.6328661
GSM967854U87-EV human glioblastoma xenograft - Control 33.6366661
GSM967855U87-EV human glioblastoma xenograft - Control 43.4893359
GSM967856U87-EV human glioblastoma xenograft - Control 53.5533560
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8929164
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8793764
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6532961
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5794660
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5814960
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.657661
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5576560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7473362
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6582161